Protara Therapeutics, Inc. Common Stock (TARA) Stock
NASDAQ · TARA
Key stats
- Market cap
- $144.19M
- Price / Earnings ratio
- -2.1x
- EPS (TTM)
- -$5.70
- Volume
- Loading
- 52-week high
- $7.82
- 52-week low
- $2.30
Source: third-party data provider, as of October 24, 2026
Compare with TARA
Recent news

Zacks Investment Research
What Makes Protara Therapeutics (TARA) a New Buy Stock
TARAJuly 21, 2026
Zacks Investment Research
What Makes Protara Therapeutics (TARA) a New Buy Stock
TARA

Stocktwits
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data?
TARAFebruary 24, 2026
Stocktwits
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data?
TARA
Technical indicators
- RSI 14
- 32.02
- MACD 12/26/9
- -0.28
- EMA 9 of MACD
- -0.30
- MACD histogram
- 0.02
- SMA 50
- $3.37
- Price below SMA 50
- EMA 50
- $3.21
- Price below EMA 50
- SMA 200
- $4.65
- Price below SMA 200
- EMA 200
- $4.46
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
251M166M83M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-57.4M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Zacks Investment Research
What Makes Protara Therapeutics (TARA) a New Buy Stock
TARAJuly 21, 2026
Zacks Investment Research
What Makes Protara Therapeutics (TARA) a New Buy Stock
TARA

Stocktwits
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data?
TARAFebruary 24, 2026
Stocktwits
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data?
TARA
About Protara Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees46
CEOMr. Jesse Shefferman
IPO DateOct 22, 2014
HeadquartersNew York, NY
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Jesse Shefferman | Co-founder, CEO, President & Director | 1972 |
| Mr. Patrick Fabbio M.B.A. | Chief Financial Officer | 1968 |
| Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder, Chief R&D Officer | 1981 |
| Ms. Hannah Fry | VP, Principal Accounting Officer & Controller | 1991 |
| Ms. Justine O'Malley | Senior Vice President of Investor Relations & Corporate Affairs | — |
| Ms. Mary J. Grendell J.D. | General Counsel & Corporate Secretary | — |
| Dr. Shane Williams Ph.D. | Chief People Officer | — |
| Mr. William Conkling | Chief Commercial Officer | 1971 |
| Carla Beckham M.D., Ph.D. | Lead Medical Director, Head of Clinical Development of TARA-002 in NMIBC & Board-Certified Urologist | — |
| Dr. Neal D. Shore F.A.C.S., M.D. | Medical Director of START Carolinas/ Carolina Urologic Research Center | — |
Fundamentals
Valuation
Price-to-book value0.92
Profitability
Return on Equity-42.00%
Return on Assets-39.00%
EBITDA$-69.67M
Trading
Average volume1,596,613
Source: third-party data provider, as of October 24, 2026
Technical indicators
- RSI 14
- 32.02
- MACD 12/26/9
- -0.28
- EMA 9 of MACD
- -0.30
- MACD histogram
- 0.02
- SMA 50
- $3.37
- Price below SMA 50
- EMA 50
- $3.21
- Price below EMA 50
- SMA 200
- $4.65
- Price below SMA 200
- EMA 200
- $4.46
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.6 | -1.9 | +2.9 | |||||||||
| 2022 | -24.5 | -17.9 | +13.6 | -27.1 | -7.2 | -15.8 | -7.1 | +10.2 | -9.2 | -4.1 | +14.2 | -21.9 |
| 2023 | +16.8 | +6.0 | -19.9 | +0.3 | -7.6 | -14.3 | +5.3 | -13.1 | -23.4 | -25.6 | +20.8 | +30.6 |
| 2024 | +21.4 | +71.4 | -12.8 | -28.0 | -4.1 | -25.7 | +6.7 | -5.2 | -4.7 | +41.0 | +21.9 | +108.7 |
| 2025 | -11.8 | -24.3 | +23.8 | -12.7 | -12.1 | -8.2 | +10.7 | +2.0 | +37.2 | +17.5 | +44.1 | -20.9 |
| 2026 | +31.6 | -9.7 | -12.7 | +5.8 | -12.6 | -15.5 | -3.0 | -2.8 | -21.8 | -11.6 |
Compare stocks
Market cap
$144.19M
-
-
-
Price / Earnings ratio
-2.10
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,596,613
-
-
-
Earnings per share
$-5.70
-
-
-



